Arcalyst FDA Approval History
Last updated by Judith Stewart, BPharm on March 30, 2021.
FDA Approved: Yes (First approved February 27, 2008)
Brand name: Arcalyst
Generic name: rilonacept
Dosage form: Injection
Previous Name: Interleukin-1 Trap
Company: Regeneron Pharmaceuticals, Inc.
Treatment for: Cryopyrin-Associated Periodic Syndromes; Deficiency of Interleukin-1 Receptor Antagonist; Recurrent Pericarditis
Arcalyst (rilonacept) is an interleukin-1 inhibitor indicated for the:
- treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older
- maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more
- treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older.
Development timeline for Arcalyst
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
